PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.66%
R&D change of 15.66% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
40.35%
G&A change of 40.35% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
24.17%
Other expenses change of 24.17% versus flat Biotechnology costs. Walter Schloss would verify efficiency.
22.03%
Operating expenses change of 22.03% versus flat Biotechnology costs. Walter Schloss would verify control.
22.03%
Total costs change of 22.03% versus flat Biotechnology costs. Walter Schloss would verify control.
-100.00%
Interest expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
24.17%
D&A change of 24.17% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
-22.02%
EBITDA decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-22.03%
Operating income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-9.98%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-22.30%
Pre-tax income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
9.98%
Tax expense change of 9.98% versus flat Biotechnology. Walter Schloss would verify strategy.
-22.30%
Net income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-22.29%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-22.29%
Diluted EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.